Cytosorbents Corp (CTSO) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cytosorbents Corporation on February 25, 2025. The report discloses the expiration of the Series A Right Warrants issued under a previously announced rights offering and details the proceeds received from warrant exercises.
Key Financial Metrics
- Warrant Exercise Proceeds: $1.6 million (aggregate gross proceeds).
- Warrants Exercised: 1,417,208 Series A Right Warrants.
- Exercise Price: $1.13 per Series A Right Warrant.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these metrics as this is a current report focused on a specific corporate event rather than a periodic financial statement.
Material Changes
The primary material change reported is the completion of the Series A Right Warrant exercise period. The company received $1.6 million in capital from the exercise of approximately 1.42 million warrants prior to their expiration.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure language regarding the press release. The event represents a completed capital raise activity.
Investor Verification Checklist
- Verify the total cash impact of the $1.6 million proceeds on the company's current liquidity position.
- Confirm the dilution impact of the 1,417,208 newly issued shares resulting from the warrant exercises.
- Review the full text of the press release (Exhibit 99.1) for any additional operational context not included in the 8-K summary.